Mammograms catch only 75% to 85% of breast cancers, and because more than half of women over 40 have dense breast tissue that hides tumors in a white background, a gynecologist who was diagnosed after a negative mammogram, ultrasound and MRI says your calculated lifetime risk, not your family history, should decide when you start imaging.

• What to do: Calculate your lifetime risk with the Tyrer-Cuzick tool using age, height, weight, breast density, family history, age at first period and menopause, and biopsy results. If it is 20% or more, start imaging as early as age 30.
• Why it matters: One in eight women, or 12.5%, develops breast cancer, and 85% have no family history. The guest had no family history or mutation, yet an atypia biopsy pushed the lifetime risk to 37%, and an invasive cancer was later found.
• How to apply it: With dense breasts, ask for a 3D mammogram and a breast ultrasound. Above 20% to 25% risk, add an annual breast MRI. Ask your doctor for genetic cancer testing by age 25, and about hormone therapy only after individual risk review.
• Metrics: Alcohol at one glass a day raised breast cancer risk by about 40% in a JAMA study cited, and polygenic risk scores above the 90th percentile flag higher risk. Useful labs include A1C, ApoB, lipoprotein(a), hs-CRP, homocysteine, vitamin D, B12 and ferritin.
• Tools: 3D mammography, breast ultrasound, breast MRI, genetic panels, the Galleri multi-cancer blood test and Function Health lab panels.
• Risks: No blood test can tell you whether you will get breast cancer. Estrogen-driven risk rises with obesity, alcohol, inactivity, xenoestrogens and an unhealthy microbiome.
• Exceptions: After an estrogen receptor positive cancer, hormone therapy is not started casually, and tamoxifen cannot be combined with hormone replacement.

Insulin resistance carried a 6.4-fold higher risk of early heart attack in a study of 28,000 people, far above hypertension at 2.3, triglycerides at 2.1 and LDL at 1.38, according to Dr. Anthony Jay, because the heart prefers to burn fat and starves when insulin resistance blocks its fuel.

• What to do: Measure fasting insulin, not just blood sugar, and aim below 5 (below 10 at the very least). After age 50, consider a CAC scan, which gives a single number with no interpretation.
• Why it matters: Jay says doctors focus on LDL and ignore insulin, a gap he links to statin and PCSK9 drug sales. He describes LDL and Lp(a) as transporters and clean-up particles, not villains.
• How to apply it: Cut the carbohydrates you cannot burn, exercise so muscle absorbs sugar without insulin, and use fasting. Avoid mixing large amounts of carbs and fats together if you are insulin resistant.
• Metrics: Fasting blood sugar below 85 usually signals good insulin, HOMA-IR combines the two tests, and Lp(a) needs to reach about 193 to hit a 1.5 hazard ratio for heart disease.
• Tools: CAC scan (about $40 to $150), an insulin test for about $15 at Own Your Labs, and electrolytes such as LMNT.
• Risks: CCTA scans use about five times more radiation than a CAC scan and varied by plus or minus 20% between scans in the same week. Do not change prescribed medication without your doctor.
• Exceptions: Young, active people can handle more carbohydrates, and some lean people on very low carb diets show high LDL as fat transport rises.

Three platforms analyzed the same two coronary CT scans and reported plaque changes of minus 48%, plus 20% and nearly flat (10.4 to 11.5 cubic millimeters), because with very little plaque and only 16.5 months between scans, measurement noise looks like a result.

• What to do: If you track plaque with coronary CT angiography, use the same provider, the same scanner and the same settings every time, and wait at least 2 to 5 years between scans, as the American College of Cardiology statement suggests.
• Why it matters: Plaque depends on cumulative exposure to ApoB, the protein on each atherogenic particle, so years at an LDL of about 125 matter even after a diet change, and no platform showed rapid progression (1 percentage point or more per year).
• How to apply it: Ask your doctor about your ApoB target, since he is aiming for 40 mg/dL or lower with Repatha (evolocumab) after sitting at 70 to 80 on a plant based diet, and keep training, sleep and diet in place.
• Metrics: ApoB 70 to 80 mg/dL, LDL 125 before diet change, calcium score 4, soft plaque down about 40% on Qangio, and a reading near the 55th percentile on Clearly versus the 80th on HeartFlow.
• Tools: Qangio, Clearly and HeartFlow for plaque analysis, aged garlic extract at 2,400 mg a day, and Eight Sleep for sleep temperature.
• Risks: AI platforms may overestimate small plaque amounts, and this is one person's plan, not a recommendation.
• Exceptions: Statins remain first line therapy and may fit you better, and some people need two drugs to reach target.

A fasting insulin above 13 in a child signals hyperinsulinemia years before A1C rises, so a normal fasting glucose can hide type 2 diabetes that has already started, as incidence in ages 10 to 19 jumped from 2.37 to 22.3 per 100,000 between 2002 and 2023.

• What to do: Ask your pediatrician for an A1C and a fasting serum insulin if your child is overweight, has dark skin patches or has a family history of type 2 diabetes. Repeat the A1C at least once a year.
• Why it matters: Incidence grew 2.9% a year from 2002 to 2013 and 4.7% a year from 2014 to 2023. A child diagnosed young has decades to damage the heart, brain, kidneys and liver.
• How to apply it: Remove added sugar first, then slowly wean off cereal, bread, crackers, chips, cookies, pasta and fruit juice. Do not restrict portions or fast. Add meat, eggs and whole vegetables, and change the whole family's diet.
• Metrics: Healthy fasting insulin is about 3.9 in young children, about 5.0 before puberty, 7.2 in boys and 8.9 in girls near age 11, and never above 13. Treat an A1C rise of 0.1 or a fasting insulin of 15 to 17 as a red flag.
• Tools: Print the pediatric insulin studies from the show notes and bring your child's weight, glucose and family history to the visit.
• Risks: Prediabetes already harms small arteries, heart, brain, kidneys and liver, and normal fasting glucose can mislead the doctor.
• Exceptions: A very low fasting insulin can point to type 1 diabetes, which needs separate testing right away.

Almost everyone over 45 has some labral or rotator cuff tear on an MRI with no pain at all, proof that imaging alone should not decide whether surgery is needed.

• What to do: before operating on a meniscus or rotator cuff tear with no clear injury, try several months of physical therapy first; sham surgery trials repeatedly show it matches surgical outcomes.
• Why it matters: phrases like "bone on bone" or "tear" trigger enough fear that people quit exercising or ask for a joint replacement too early, even though imaging findings don't reliably match symptoms.
• How to apply it: starting at 50, add power, balance and plyometric work to your routine, not just strength, because most falls happen when you can't recover your balance in time, not from a lack of strength.
• Risks: gray-market peptides like BPC-157 or TB-500 have no long-term safety data, and injecting them into a joint can cause an infection that permanently destroys cartilage.
• Exceptions: a meniscus root tear usually does need prompt surgical repair, since the knee deteriorates quickly if it's left untreated.

Without enough fiber, your gut bacteria start eating the mucous layer that protects your gut lining instead of the fiber itself, a shift gastroenterologist Dr. Chris Thompson calls a snowball effect that undermines the tight junctions holding your gut barrier together.

• What to do: Aim for roughly 35 grams of fiber a day if you are a man and 25 grams if you are a woman, and add low sugar fermented foods like kimchi, sauerkraut, kefir, or yogurt alongside it.
• Why it matters: Fiber alone supports regularity, but research from Stanford's Justin Sonnenburg found fermented foods specifically increase microbiome diversity and lower inflammatory markers in ways fiber did not match in that study.
• How to apply it: If you are on a GLP1 medication, pair it with resistance training to preserve muscle, since about a third of the weight lost on these drugs is lean mass, and consider a DEXA scan beforehand if you are worried about your starting muscle reserves.
• Metrics: Roughly a third of GLP1 users stop within the first month and about half by the end of the year, similar to dropout rates for blood pressure and cholesterol medications.
• Tools: Cologuard style stool based genetic tests every few years, or a screening colonoscopy every ten years if results are normal, starting at 45 or ten years before a family member's diagnosis age.
• Exceptions: Microdosing a GLP1 instead of stopping outright is not an official recommendation, but some clinicians report it helps patients maintain weight loss with fewer side effects.

A two month tendon building phase followed by strength and rate of force development work gives this 49 year old an estimated 80 to 85 percent chance of dunking a basketball, according to his NBA level trainer.

• What to do: Spend the first 8 to 12 weeks on tendon loading work, hinge positions, controlled dips, calf raises, and squat variations, before adding any jumping or plyometric drills.
• Why it matters: Tendons need 8 to 12 weeks to remodel and stiffen, while muscle adapts in 3 to 4 weeks, so jumping straight into explosive training is a common way people over 40 get injured chasing a fast result.
• How to apply it: Once the tendon base is built, layer in strength training, then shift to rate of force development drills so raw strength turns into speed off the ground instead of just heavier lifts.
• Metrics: Baseline vertical jump of about 23 to 24 inches, target VO2 max in the mid 50s, the range typical of an elite 18 year old.
• Risks: Skipping the foundation phase to rush toward plyometrics raises injury risk, no matter how strong someone already is.

ZEUS suppressed CRP by the largest margin any anti-inflammatory heart trial has achieved, yet its hazard ratio for cardiovascular events landed at 0.99, a near-exact null result that shows lowering a blood marker doesn't guarantee lowering actual heart attack risk.

• What to do: Don't treat a single CRP reading as proof of high or low cardiovascular inflammation risk on its own; ask your doctor how it fits with your LDL, Lp(a) and overall risk profile instead of reacting to that number in isolation.
• Why it matters: Mendelian randomization studies show genetic variants that change CRP levels don't change cardiovascular disease risk, while variants that change LDL or Lp(a) do, so CRP is a correlated marker of inflammation, not a proven causal driver of heart disease.
• How to apply it: If you have a high Lp(a) on a blood test, know that current Lp(a)-lowering drugs still haven't proven a cardiovascular benefit in a completed phase 3 trial; aggressive LDL management remains the well-proven lever available today.
• Metrics: ZEUS enrolled over 6,300 patients with kidney disease and CRP above 2 mg/L; HORIZON enrolled about 8,300 patients with Lp(a) above 70 mg/dL and lowered Lp(a) by 70 to 80%, likely short of the roughly 100 mg/dL reduction modeling suggested was needed.
• Tools: Newer research is shifting from blood-based markers like CRP toward direct imaging of coronary artery inflammation, such as PET-MRI and CT-based fat attenuation index scans, to select patients more precisely for future anti-inflammatory drug trials.